Back to today’s briefing

Story perspectives

BioNTech Acquires CureVac for $1.25 Billion in Stock

6/13/2025

26 4

Summary

Story summary

BioNTech is set to acquire CureVac for a staggering $1.25 billion in an all-stock deal, marking a significant leap in its mission to revolutionize mRNA-based cancer therapies. With CureVac shareholders enjoying a 55% premium, this acquisition not only resolves patent disputes but also fortifies BioNTech's foothold in the competitive German market for cutting-edge cancer treatments.

1 of 1

Story summary

BioNTech is set to acquire CureVac for a staggering $1.25 billion in an all-stock deal, marking a significant leap in its mission to revolutionize mRNA-based cancer therapies. With CureVac shareholders enjoying a 55% premium, this acquisition not only resolves patent disputes but also fortifies BioNTech's foothold in the competitive German market for cutting-edge cancer treatments.